Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium
ECONOMY & POLICY

Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation.

Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as "the future of cancer treatment". Rosatom and healthcare facilities are actively working in this field.

"Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science," said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC.

The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation. Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as the future of cancer treatment. Rosatom and healthcare facilities are actively working in this field. Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science, said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC. The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

Related Stories

Gold Stories

Next Story
Infrastructure Energy

Asian Energy Services Q1 FY27 PAT Rises 129 Per Cent

Asian Energy Services Limited reported a 129 per cent year-on-year rise in net profit to Rs 128 million for Q1 FY27, compared with the corresponding quarter last year.Revenue increased 135 per cent year-on-year to Rs 2.71 billion, supported by continued momentum across its services business, disciplined execution and contributions from domestic and international operations. EBITDA grew 81 per cent year-on-year during the quarter.As of June 30, 2026, the company’s standalone order book stood at Rs 17.54 billion, with around 60 per cent coming from oil and gas services and 40 per cent from min..

Next Story
Infrastructure Urban

BioBTX to Build First Commercial-Scale Circular Chemicals Plant

Dutch circular chemistry technology developer BioBTX is building what it says will be the world’s first commercial-scale plant to convert mixed plastic waste into high-quality aromatic chemicals using its proprietary Integrated Catalytic Cracking Process (ICCP) technology.The facility will be built at Chemical Park Delfzijl on the northern coast of the Netherlands and is expected to create 35 jobs. Covestro, which has been a shareholder and strategic partner of BioBTX since 2024, holds a mid-single-digit million-euro investment in the company.BioBTX’s ICCP technology uses catalytic pyrolys..

Next Story
Real Estate

Awfis Q1 FY27 PAT Jumps 140% as Revenue Rises 27%

Awfis Space Solutions reported a 140 per cent year-on-year rise in consolidated profit after tax (PAT) to Rs 240 million for Q1 FY27, compared with Rs 100 million in the corresponding quarter last year.Revenue from operations increased 27 per cent to Rs 4.25 billion from Rs 3.35 billion, while EBITDA rose 28 per cent to Rs 1.62 billion. EBITDA margin improved to 38.2 per cent from 37.8 per cent. Profit before tax increased 135 per cent to Rs 240 million.The company's co-working business recorded 27 per cent year-on-year growth, supported by demand from enterprises, Global Capability Centres (G..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement